Name | (2E,5S,6S,8Z,11S)-5,6,15-trihydroxy-17-methoxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,8,15,17-pentaene-7,13-dione |
---|---|
Synonyms |
(3s,5z,8s,9s,11e)-8,9,16-Trihydroxy-14-Methoxy-3-Methyl-3,4,9,10-Tetrahydro-1h-2-Benzoxacyclotetradecine-1,7(8h)-Dione
LL-Z1640-2 AmbotzLS-1148 5Z-7-Oxozeaenol |
Description | 5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively. |
---|---|
Related Catalog | |
Target |
TAK1:8.1 nM (IC50) MEK1:411 nM (IC50) VEGFR-2:52 nM (IC50) VEGFR-3:110 nM (IC50) FLT3:170 nM (IC50) PDGFR-β:340 nM (IC50) B-RAF VE:6300 nM (IC50) SRC:6600 nM (IC50) |
In Vitro | 5Z-7-Oxozeaenol is a potent irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 (TAK1, IC50, 8.1 nM), less active on MEK1 (IC50, 411 nM). 5Z-7-Oxozeaenol prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase[1]. 5Z-7-Oxozeaenol is also an inhibitor of VEGF-R2, with an IC50 of 52 nM. 5Z-7-Oxozeaenol has inhibitory activity against VEGF-R3, FLT3, PDGFR-β, B-RAF VE and SRC, with IC50s of 110, 170, 340, 6300 and 6600 nM, respectively[2]. 5Z-7-Oxozeaenol inhibits JNK/p38 paythway, but it is not a direct inhibitor and is signal specific. 5Z-7-Oxozeaenol suppresses the PMA-induced AP-1 activity almost to the basal level in the KT cells, but has no effects on IL-1-induced NF-kB activity in the KK cells[3]. |
Kinase Assay | For screening TAK1 inhibitors, insect expression vectors for TAK1 and TAB1 are co-infected into Sf9 cells. After 2 days of incubation, cell lysates are immunoprecipitated with anti-TAK1 antibody (M-17). The immunoprecipitates are incubated with various compounds (5Z-7-Oxozeaenol, etc.) and subsequently incubated with 2 μg of myelin basic protein and 10 μCi of [γ-32P]ATP (3,000 Ci/mmol) in 10 μL of the kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl2 at 30°C for 5 min. Samples are separated by 10% SDS-PAGE, and 32P incorporated into myelin basic protein is quantified with a bioimage analyzer. The catalytic activity of MEK1 is determined by activation of ERK2 to phosphorylate dure. The catalytic activity of MEKK1 is measured with 2 μg of myelin basic protein as a substrate in the kinase buffer. For subsequent kinase assays, immunoprecipitates are incubated with 5 μCi of [γ-32P]ATP (3,000 Ci/mmol) and 1 μg of bacterially expressed MKK6 or GST-IκBα-(1-72) in 10 μL of the kinase buffer at 25°C for 2 min. Samples are separated by 10% SDS-PAGE and visualized by autoradiography[1]. |
References |
Molecular Formula | C19H22O7 |
---|---|
Molecular Weight | 362.37400 |
Exact Mass | 362.13700 |
PSA | 113.29000 |
LogP | 1.60020 |
Storage condition | 2-8℃ |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
RIDADR | UN 2811 6.1 / PGIII |
Precursor 0 | |
---|---|
DownStream 1 | |